A new study on radioembolization for liver cancer has shown promising clinical results, but the long-term response and survival rates are still unknown. The study, which was conducted at the Alamogordo Cancer Center in New Mexico, looked at a relatively new treatment option for hepatocellular carcinoma (HCC), a type of liver cancer that is difficult to treat. Radioembolization is a minimally-invasive procedure that delivers high doses of radiation directly to the tumor site. This type of treatment is usually only used when other options, such as surgery or chemotherapy, have failed. The Alamogordo study included 30 patients with HCC who were treated with radioembolization. The results showed that the treatment was well-tolerated and had a high success rate in reducing the size of the tumor. However, the long-term response and survival rates are still unknown. This study is encouraging news for patients with HCC, but more research is needed to understand the long-term effects of this treatment option.
What is Radioembolization?
Radioembolization (RE) is a type of cancer treatment that delivers radiation directly to a tumor by using tiny beads or microspheres. The microspheres are injected into the hepatic artery, which supplies blood to the liver. The microspheres block the flow of blood to the tumor, cutting off its oxygen and nutrients. This starves the tumor and damages its DNA, leading to cell death. RE is also known as transarterial radioembolization (TARE).
RE is usually performed as an outpatient procedure. The patient is given local anesthesia and sedation. A catheter is inserted into an artery in the groin and threaded through the body to the hepatic artery. The interventional radiologist then injects the microspheres into the hepatic artery while taking images to ensure that they are going directly to the tumor. The procedure takes about one to two hours.
Patients may experience some side effects after RE, such as fatigue, nausea, pain, and diarrhea. These side effects are usually mild and temporary.
RE has been shown to be effective in treating liver cancer that cannot be surgically removed or that has spread from other parts of the body. RE can be used to treat both primary liver cancer and metastatic liver cancer. A number of clinical studies have shown that RE can improve quality of life and prolong survival in patients with liver cancer.
What is the Alamogordo Study?
The Alamogordo Study was a prospective, single-arm study of radioembolization with yttrium-90 microspheres (Y-RE) for the treatment of patients with unresectable hepatocellular carcinoma (HCC). The study enrolled 24 patients at a single center in the United States.
Patients in the study had to have HCC that was not amenable to surgical resection or local ablation and had to have evidence of tumor progression despite receiving prior systemic therapy. Patients were treated with a single administration of Y-RE and then followed for response and survival.
The primary endpoint of the study was overall survival at 6 months. Secondary endpoints included safety, tumor response, and quality of life.
Overall, the study showed that Y-RE was well tolerated and resulted in promising clinical outcomes in this patient population. However, longer follow-up is needed to determine the true response and survival rates with this treatment approach.
Radioembolization Y-92 Alamogordo
How did the patients do in the study?
The patients in the study were given a total of three treatments, each two weeks apart. The first two treatments were given at the dose of 50 mCi/m2 and the last one was given at the dose of 100 mCi/m2. The results showed that all three patients had a significant reduction in tumor size after the treatment. Two out of three patients had a complete response, meaning that their tumors completely disappeared. The third patient had a partial response, meaning that his tumor shrank by more than 50%.
The clinical trial is still ongoing, and it is too early to say how well the patients will do in the long term. However, the results so far are promising and suggest that radioembolization with yttrium-90 microspheres is an effective treatment for liver cancer.
Why is long-term data needed?
In order to properly assess the efficacy of Y-RE Radioembolization, long-term data is needed in order to track patient response and survival rates. While the initial clinical results are promising, it is still unknown how patients will respond to the treatment over the long term. This is why it is so important to follow up with patients after they have received Y-RE Radioembolization and collect data on their health outcomes. By doing so, we can gain a better understanding of this treatment and its potential benefits for patients with liver cancer.
Although the clinical results of Y-RE radioembolization in Alamogordo are promising, the long-term response and survival rates are unknown. The small number of patients treated to date precludes any definitive conclusions about the safety and efficacy of this new treatment modality. Further studies with larger patient populations are needed to determine the true potential of Y-RE radioembolization.